| Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. | |
| | |
MedLine Citation:
|
PMID: 17222546 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: Our goal was to examine to what extent tumour volume (TV) and percentage of high grade tumour volume (%HGTV) affect the rate of positive surgical margins and the rate of biochemical recurrence after radical prostatectomy. MATERIALS AND METHODS: TV and %HGTV were routinely planimetrically quantified in a cohort of 780 consecutive patients. Mean follow-up was 46.7 months. Multivariable regression models addressed two separate endpoints: positive surgical margins and biochemical recurrence. The increase in model predictive accuracy related to the addition of TV and %HGTV to radical prostatectomy stage and grade was assessed, after 200 bootstrap resamples to reduce overfit bias. RESULTS: In multivariable logistic regression models addressing positive surgical margins rate, predictive accuracy increased by 1.9% (p<0.001) when TV was added to other covariates. No further increment was noted when %HGTV was added (p=0.3). In multivariable Cox regression models addressing biochemical recurrence, accuracy increased by 0.6% (p=0.002) when TV was added and an additional increase of 0.7% was recorded when %HGTV (p<0.001) was added. CONCLUSION: Tumour bulk reflected by TV affects local cancer control rate, which is reflected in the rate of positive surgical margins. Conversely, high grade cancer determines the rate of biochemical recurrence. These two variables represent the most powerful predictors of cancer control in men treated for localised prostate cancer. Moreover, they increase the ability of established predictors to predict the outcomes of interest. In consequence, they warrant consideration in future predictive and prognostic tools. |
| | |
Authors:
|
Felix K-H Chun; Alberto Briganti; Claudio Jeldres; Andrea Gallina; Andreas Erbersdobler; Thorsten Schlomm; Jochen Walz; Christian Eichelberg; Georg Salomon; Alexander Haese; Eike Currlin; Sascha A Ahyai; François Bénard; Hartwig Huland; Markus Graefen; Pierre I Karakiewicz |
Related Documents
:
|
12007976 - The evolving role of systemic therapy in high risk prostate cancer: strategies for cure... 12385936 - Technique of modern radical perineal prostatectomy. 17532856 - Low nuclear erbb3 predicts biochemical recurrence in patients with prostate cancer. 22084396 - Intermittent administration of mek inhibitor gdc-0973 plus pi3k inhibitor gdc-0941 trig... 22532266 - Incidence and management of gastrointestinal perforation from bevacizumab in advanced c... 12566716 - Restoration of fertility after treatment for cancer. |
Publication Detail:
|
Type: Journal Article Date: 2007-01-11 |
Journal Detail:
|
Title: European journal of cancer (Oxford, England : 1990) Volume: 43 ISSN: 0959-8049 ISO Abbreviation: Eur. J. Cancer Publication Date: 2007 Feb |
Date Detail:
|
Created Date: 2007-02-05 Completed Date: 2007-05-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9005373 Medline TA: Eur J Cancer Country: England |
Other Details:
|
Languages: eng Pagination: 536-43 Citation Subset: IM |
Affiliation:
|
Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), 1058, Rue St-Denis, Montreal, Que., Canada H2X 3J4. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Disease-Free Survival Follow-Up Studies Humans Male Middle Aged Neoplasm Recurrence, Local / pathology Neoplasm Staging / methods* Organ Size Prostate / pathology Prostate-Specific Antigen / blood Prostatectomy / methods Prostatic Neoplasms / blood, pathology*, surgery |
| Chemical | |
Reg. No./Substance:
|
EC 3.4.21.77/Prostate-Specific Antigen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ten-year survival and risk of relapse for testicular cancer: a EUROCARE high resolution study.
Next Document: Allelic variants of CAMTA1 and FLJ10737 within a commonly deleted region at 1p36 in neuroblastoma.